Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC19H24ClN5O3S |
InChIKeyAXAOJXUYQVCGBD-LLVKDONJSA-N |
CAS Registry2409825-32-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Preclinical | Switzerland | 04 Jan 2024 | |
Arthritis, Gouty | Preclinical | Switzerland | 04 Jan 2024 | |
Atherosclerosis | Preclinical | Switzerland | 04 Jan 2024 | |
Diabetes Mellitus, Type 2 | Preclinical | Switzerland | 04 Jan 2024 | |
Neoplasms | Preclinical | Switzerland | 04 Jan 2024 |